Working capacity and cervical dystonia

Parkinsonism and Related Disorders

Volumn 16, Issue 3, 2010, Pages 215-217

  Martikainen, Kirsti K ^a   Luukkaala, Tiina H ^b,c   Marttila, Reijo J ^d  

^a The Finnish Parkinson Association and Foundation   (Finland)

^b PIRKANMAA HOSPITAL DISTRICT   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Cervical dystonia; Employment; Rehabilitation; Retirement; Working capacity

Indexed keywords

ANTIDEPRESSANT AGENT; BOTULINUM TOXIN;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; DISEASE DURATION; EMPLOYMENT STATUS; FEMALE; FINLAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PARTTIME EMPLOYMENT; PHYSIOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; RETIREMENT; SYMPTOM; UNEMPLOYMENT; WORK CAPACITY;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; EMPLOYMENT; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PROBABILITY; QUESTIONNAIRES; RETIREMENT; TORTICOLLIS; WORK; WORK CAPACITY EVALUATION;

EID: 76849092542     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2009.07.006     Document Type: Article

References (11)

1. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 247 (2000) 787-792
2. Erjanti H.M., Marttila R.J., and Rinne U.K. The prevalence and incidence of cervical dystonia in south-western Finland. Mov Disord 11 Suppl. 1 (1996) 215
3. Skogseid I.M., Rǿislien J., Claussen B., and Kerty E. Long-term Botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20 (2005) 1604-1609
4. Ben-Shlomo Y., Camfield L., Warner T., and on behalf of the ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia?. J Neurol Neurosurg Psychiatry 72 (2002) 608-614
5. Müller J., Kemmler G., Wissel J., Schneider A., Voller B., Grossmann J., et al., and the Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249 (2002) 842-846
6. Müller J., Wissel J., Kemmler G., Voller B., Bodner T., Schneider A., et al., and the Austrian Botulinum Toxin and Dystonia Study Group. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 75 (2004) 749-753
7. Statistical Yearbook of Finland 2005 (2005), Gummerus kirjapaino Oy, Jyväskylä pp. 373-374
8. Spliethoff-Kamminga N.G.A., Zimmerman A.H., Springer M.P., and Roos R.A.C. Difference in quality of life and psychosocial well-being between Parkinson disease patient members and non-members of the Dutch Parkinson Disease Association. In: Noëlle G.A., and Spliethoff- Kamminga N.G.A. (Eds). Psychosocial Problems in Parkinson's Disease (2004), Graphische Producties, Universitair Facilitair Bedrijf, Leiden 79-89
9. Hilker R., Schischniasvili M., Ghaemi M., Jacobs A., and Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 71 (2001) 193-199
10. Brefel-Courbon C., Simonetta-Moreau M., Moré C., Rascol O., Clanet M., Montastruc J.-L., et al. A pharmacoeconomic evaluation of Botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 23 (2000) 203-207
11. Jahanshahi M. Psychosocial factors and depression in torticollis. J Psychosom Res 35 4-5 (1991) 493-507